GA
ACAD icon

Geneva Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Geneva Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$527K Buy
18,893
+891
+5% +$26.6K 0.01% 503
2017
Q1 		$619K Buy
18,002
+1,396
+8% +$49.3K 0.01% 450
2016
Q4 		$479K Buy
+16,606
New +$439K 0.01% 489

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Geneva Advisors's ACAD Position: Q2 2017 in Review

Geneva Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 4.9% in Q2 2017, buying an estimated $26.6K and bringing the position to 18,893 shares worth $527K. The position accounts for 0.01% of the portfolio, ranked #503.

Geneva Advisors first reported a position in ACAD in Q4 2016 and has held it in 3 quarters since. The position peaked at $619K in Q1 2017. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Geneva Advisors held 18,893 shares of Acadia Pharmaceuticals worth $527K as of Q2 2017.
  • Geneva Advisors bought 891 Acadia Pharmaceuticals shares in Q2 2017, an estimated $26.6K.
  • Acadia Pharmaceuticals made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #503 holding.
  • Geneva Advisors first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 3 quarters since.
  • Geneva Advisors's Acadia Pharmaceuticals position peaked at $619K in Q1 2017.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.